KENILWORTH, NJ (April 12, 2004) – Warrick Pharmaceuticals, a wholly owned subsidiary of Schering-Plough Corp., has launched a generic ribavirin product in the United States.
Schering-Plough had previously entered into a licensing agreement with Three Rivers Pharmaceuticals, LLC regarding U.S. ribavirin patents. Under terms of the agreement and as a result of launching Warrick ribavirin, Schering-Plough will not receive a royalty from Three Rivers on sales of Three Rivers’ generic ribavirin product, the company said. Financial terms of the licensing agreement have not been disclosed.Schering-Plough noted that the market for generic pharmaceutical products is volatile, particularly at launch, and it will price its generic ribavirin product according to market conditions and applicable regulations.
Schering-Plough markets ribavirin USP capsules under the brand name Rebetol. The company said it expected generic competition for Rebetol in the U.S. market in 2004.
Schering-Plough is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide.